Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $16.00 price target on the biopharmaceutical company’s stock.

ESPR has been the subject of a number of other research reports. JMP Securities reissued a “market outperform” rating and issued a $7.00 price objective on shares of Esperion Therapeutics in a report on Thursday, January 23rd. Cantor Fitzgerald began coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price objective on the stock. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $6.75.

Esperion Therapeutics Stock Up 5.0 %

ESPR stock opened at $1.88 on Tuesday. The company has a market cap of $370.44 million, a price-to-earnings ratio of -2.94 and a beta of 1.01. Esperion Therapeutics has a twelve month low of $1.58 and a twelve month high of $3.94. The business has a 50 day moving average price of $2.28 and a two-hundred day moving average price of $2.12.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company purchased a new position in Esperion Therapeutics in the second quarter valued at approximately $159,000. SG Americas Securities LLC lifted its position in shares of Esperion Therapeutics by 105.9% during the 3rd quarter. SG Americas Securities LLC now owns 77,049 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 39,635 shares during the last quarter. Boomfish Wealth Group LLC grew its stake in shares of Esperion Therapeutics by 17.1% during the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after acquiring an additional 5,102 shares during the period. Traphagen Investment Advisors LLC purchased a new stake in Esperion Therapeutics in the 3rd quarter worth about $27,000. Finally, Versor Investments LP purchased a new stake in Esperion Therapeutics during the third quarter valued at about $44,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.